Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma | Zendy

Caroline Robert | Zendy; JeanJacques Grob | Zendy; Daniil Stroyakovskiy | Zendy; Bogusława Karaszewska | Zendy; Axel Hauschild | Zendy; E. Levchenko | Zendy; Vanna ChiarionSileni | Zendy; Jacob Schachter | Zendy; Claus Garbe | Zendy; Igor Bondarenko | Zendy; Helen Gogas | Zendy; Mario Mandalà | Zendy; John B.A.G. Haanen | Zendy; Célèste Lebbé | Zendy; Andrzej Maćkiewicz | Zendy; Piotr Rutkowski | Zendy; Paul Nathan | Zendy; Antoni Ribas | Zendy; Michael A. Davies | Zendy; Keith T. Flaherty | Zendy; Paul Burgess | Zendy; Monique Tan | Zendy; Eduard Gasal | Zendy; Maurizio Voi | Zendy; Dirk Schadendorf | Zendy; Georgina V. Long | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

Author(s) -

Caroline Robert,

JeanJacques Grob,

Daniil Stroyakovskiy,

Bogusława Karaszewska,

Axel Hauschild,

E. Levchenko,

Vanna ChiarionSileni,

Jacob Schachter,

Claus Garbe,

Igor Bondarenko,

Helen Gogas,

Mario Mandalà,

John B.A.G. Haanen,

Célèste Lebbé,

Andrzej Maćkiewicz,

Piotr Rutkowski,

Paul Nathan,

Antoni Ribas,

Michael A. Davies,

Keith T. Flaherty,

Paul Burgess,

Monique Tan,

Eduard Gasal,

Maurizio Voi,

Dirk Schadendorf,

Georgina V. Long

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1904059

Subject(s) - dabrafenib , trametinib , medicine , metastatic melanoma , melanoma , oncology , mek inhibitor , overall survival , clinical trial , randomized controlled trial , vemurafenib , progression free survival , cancer research , mapk/erk pathway , kinase , biology , microbiology and biotechnology

Patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation have prolonged progression-free survival and overall survival when receiving treatment with BRAF inhibitors plus MEK inhibitors. However, long-term clinical outcomes in these patients remain undefined. To determine 5-year survival rates and clinical characteristics of the patients with durable benefit, we sought to review long-term data from randomized trials of combination therapy with BRAF and MEK inhibitors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research